Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone513-579-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$704.59 million
Profitability
Miscellaneous
Employees2,900
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) issued its earnings results on Monday, July, 29th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.63 by $0.18. The business earned $214.10 million during the quarter, compared to analysts' expectations of $200.99 million. Medpace had a return on equity of 17.65% and a net margin of 11.28%. Medpace's quarterly revenue was up 25.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace updated its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.
What price target have analysts set for MEDP?
4 Wall Street analysts have issued 12 month target prices for Medpace's stock. Their predictions range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.6667 in the next year. This suggests that the stock has a possible downside of 7.8%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
News articles about MEDP stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Medpace.
Are investors shorting Medpace?
Medpace saw a increase in short interest in July. As of July 15th, there was short interest totalling 2,844,200 shares, an increase of 10.8% from the June 15th total of 2,567,300 shares. Based on an average trading volume of 349,500 shares, the short-interest ratio is presently 8.1 days. Approximately 10.5% of the company's shares are short sold. View Medpace's Current Options Chain.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and BIOQUAL (BIOQ).
What other stocks do shareholders of Medpace own?
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.64%), Vanguard Group Inc. (10.19%), Wasatch Advisors Inc. (5.59%), Pendal Group Ltd (4.29%), Acadian Asset Management LLC (3.45%) and APG Asset Management N.V. (1.70%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Bank of America Corp DE, Royal Bank of Canada, Acadian Asset Management LLC, D. E. Shaw & Co. Inc., ClariVest Asset Management LLC, Bernzott Capital Advisors and Chicago Equity Partners LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., APG Asset Management N.V., BlackRock Inc., Price T Rowe Associates Inc. MD, Invesco Ltd., Tributary Capital Management LLC, Marshall Wace LLP and Morgan Stanley. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $80.96.
How big of a company is Medpace?
Medpace has a market capitalization of $2.91 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
